Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. Development of Fibrin-Specific Nuclear Probe to Reduce LVAD Adverse Events

    SBC: CAPELLA IMAGING, LLC            Topic: NHLBI

    Despite the myriad major advances in cardiologythe prognosis for patients with severemedically refractive heart failureHFis exceedingly poorApproximatelydeaths occur annually in patients with HF who have endured an impaired quality of life often accompanied by significant economic and personal losses due to recurrent hospitalizationsAt leastof these deaths were directly related to severe heart fai ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Using Augmented Reality To Make Cardiac Ablation Procedures Simpler and Safer

    SBC: SENTIAR, INC.            Topic: NHLBI

    TBD

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. A robust heterologous expression system of intact fungal secondary metabolite gene clusters for natural product discovery in Aspergillus nidulans

    SBC: Intact Genomics Inc.            Topic: NCCIH

    PROJECT SUMMARY The economic and social burden for the treatment of chronic and infectious diseases is enormousandgt $BThe emergence of drug resistant microbesthe diminishing supply of novel classes of antibioticsand the dramatic reduction in discovery and development of anti infectiveanti proliferation and anti inflammation agents have further amplified public health concernFungi are prolific pro ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide

    SBC: FirstString Research, Inc            Topic: 102

    PROJECT SUMMARY GlioblastomaGBMis an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomideTMZEfforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brainIn contrastsensitizing GBM to TMZ is an appealing strategy because TMZ has excelle ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Administrative Supplement to Promote Diversity in Research and Development Small Businesses

    SBC: Neuroene Therapeutics, LLC            Topic: NINDS

    Abstract Neuroene Therapeutics is a biotech company established to develop and commercialize safe effective therapies for epilepsyinpeople develop epilepsy in their lifetimehowever the currently available anti epileptic drugsAEDshave several issues and liabilities that leave unmet market needssuch asnot controlling seizures forof patients with epilepsycurrent AEDs only treat the symptoms of epilep ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. ErythroMer: Nanoscale Bio-Synthetic Red Cell Substitute

    SBC: KaloCyte Inc            Topic: NHLBI

    PROJECT SUMMARY There is need for an artificial oxygenOcarrier to substitute for banked blood in settings wherestored blood is unavailablepre hospital care transportaustere environmentsundeveloped countriesorundesirabletransfusion risk exceeds benefitTo address this needwe developedErythroMerEMa first inclass nano cyte blood substituteEM is a deformablecross linked polymeric nanoparticle that inco ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Antithrombotic Therapy with No Bleeding Risk for PCI

    SBC: APT THERAPEUTICS, INC.            Topic: y

    Adjunctive antithrombotic treatment with dual antiplatelet therapyaspirinP Yantagonistplus anticoagulantheparin or bivalirudinis a guideline mandated for percutaneous coronaryinterventionPCIpatientsDespite aggressive antithrombotic therapyhowevermyocardialperfusion after PCI remains inadequate in many patientsReocclusion from recurrent thrombosiscontinues to occurand dose limiting bleeding occurs ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government